|
**Overview**: Hemochromatosis HFE Genotyping Panel**Introduction**: The Hemochromatosis HFE Genotyping Panel is a diagnostic tool designed to screen for hemochromatosis using whole blood samples. In India, hereditary hemochromatosis (HFE mutations C282Y, H63D, S65C) is rare but underdiagnosed in patients with unexplained liver disease, diabetes, arthropathy, or high ferritin/transferrin saturation, leading to iron overload and cirrhosis. High morbidity from under-testing in rural/low-SES patients with fatigue or joint pain, limited genetic labs, delayed phlebotomy leading to irreversible organ damage. Per molecular pathology practices aligned with ICMR and Indian Society of Gastroenterology guidelines, the test employs PCR for HFE mutations over 1-2 days with high accuracy, valuable for confirming hereditary hemochromatosis in suspected cases. This diagnostic falls under genetic disorder screening and targets patients with iron overload or family history, addressing accurate detection to guide phlebotomy and monitoring. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing iron overload complications. Its whole blood-based approach ensures reliable mutation detection.**Other Names**: HFE Geno Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: HFE genotyping standard; in India, used in liver clinics.**Purpose**: The test assesses 3 parameters including HFE C282Y mutation to guide hemochromatosis screening, detect genetic risk, inform phlebotomy.**Test Parameters**: 1. HFE C282Y Mutation, 2. HFE H63D Mutation, 3. HFE S65C Mutation.**Pretest Condition**: No fasting required; patients should report fatigue, joint pain, or family history.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on liver function, diabetes, family iron overload.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated hemochromatosis including cirrhosis, benefits of confirmation, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Homozygous C282Y or compound heterozygous indicates hemochromatosis risk, necessitating specialist input.**Specialist Consultation**: Hepatologists or geneticists should be consulted for management.**Additional Supporting Tests**: Serum ferritin, transferrin saturation for confirmation.**Test Limitations**: Limited to common HFE mutations; comprehensive approach required.**References**: Indian Journal of Gastroenterology 2024, Hemochromatosis Studies India 2023. |
